Business
We are continuing to invest in the Fitbone technology platform in order to offer surgeons more innovative solutions designed to treat limb length discrepancies and complex deformities.
Orthofix Medical Inc.: Revenue grew 2.9% to $822M from $799M. Net loss narrowed to $92.19M from $126M. Free-cash outflow narrowed to $1.279M from $9.086M. Operating margin expanded 68 bps to -9.90%. Orthofix Medical Inc.'s annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 2.9% to $822M from $799MOK
- Profitability — Net loss narrowed to $92.19M from $126MOK
- Cash flow — Free-cash outflow narrowed to $1.279M from $9.086MOK
- Margins — Operating margin expanded 68 bps to -9.90%OK
- Accounting — Distress-range screen needs contextWatch
- Insiders — 8 purchases and 21 salesOK
Where the revenue comes from
Fiscal 2025, as Orthofix Medical Inc. reports it. History and quarterly detail are in the app.
- Global Spine$687.7M
- Global Limb Reconstruction$134.7M
Leadership changes
From Orthofix Medical Inc.'s own filings, the day they're filed.
- Kimberley A. Elting On · President · departureeff. 2024-06-20
- John B. Henneman III · departureeff. 2024-06-20
- Kimberley A. Elting · President · departureeff. 2024-06-20
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-05-21
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Orthofix Medical Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.